UVA of prognostic factors in LBCL treated with anti-CD19 CAR T cells
| . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P∗ . | HR . | 95% CI . | P∗ . | |
| Age, years > 65 (vs ≤ 65) | 0.87 | 0.51-1.48 | .61 | 1.40 | 0.70-2.80 | .34 |
| Sex, M (vs F) | 1.15 | 0.67-1.95 | .61 | 1.36 | 0.65-2.86 | .42 |
| ECOG PS, ≥2 (vs <2) | 1.40 | 0.76-2.60 | .28 | 1.92 | 0.91-4.04 | .09 |
| B symptoms, yes (vs no) | 1.69 | 0.80-3.57 | .17 | 2.00 | 0.78-5.20 | .16 |
| Stage, III-IV (vs I-II) | 1.89 | 0.95-3.73 | .07 | 1.37 | 0.59-3.16 | .46 |
| Lines before leukapheresis, ≥4 (vs <4) | 1.63 | 0.90-2.98 | .11 | 1.95 | 0.94-4.03 | .07 |
| LDH, U/L, >ULN (vs ≤) ULN | 1.75 | 0.95-3.24 | .07 | 3.39 | 1.19-9.67 | .02 |
| CRP, mg/mL, >30 (vs ≤ 30) | 1.58 | 0.91-2.76 | .11 | 2.20 | 1.09-4.42 | .02 |
| Ferritin, μg/L, >1 000 (vs <1 000) | 1.27 | 0.72-2.23 | .41 | 2.36 | 1.15-4.84 | .02 |
| MTV D−7, >80 (vs < 80) | 1.58 | 0.85-2.95 | .15 | 1.93 | 0.89-4.18 | .10 |
| mHLA-DR D−7, Ab/c <13 500 | 3.17 | 1.51-6.67 | .002 | 3.15 | 1.25-7.93 | .01 |
| Lymphoma subtype | ||||||
| DLBCL (vs tNHL) | 1.65 | 0.91-2.97 | .10 | 1.24 | 0.59-2.62 | .57 |
| PMBCL (vs tNHL) | 0.55 | 0.13-2.42 | .43 | 0.00 | 0.00-0.00 | .99 |
| Cell of origin, non-GC (vs GC) | 1.38 | 0.81-2.36 | .23 | 1.15 | 0.57-2.31 | .70 |
| Prior autologous transplant, Yes (vs no) | 1.19 | 0.67-2.10 | .56 | 1.39 | 0.66-2.93 | .38 |
| CAR T-cell type, Tisa-cel (vs axi-cel) | 2.04 | 1.21-3.45 | .008 | 1.59 | 0.79-3.20 | .19 |
| . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|
| HR . | 95% CI . | P∗ . | HR . | 95% CI . | P∗ . | |
| Age, years > 65 (vs ≤ 65) | 0.87 | 0.51-1.48 | .61 | 1.40 | 0.70-2.80 | .34 |
| Sex, M (vs F) | 1.15 | 0.67-1.95 | .61 | 1.36 | 0.65-2.86 | .42 |
| ECOG PS, ≥2 (vs <2) | 1.40 | 0.76-2.60 | .28 | 1.92 | 0.91-4.04 | .09 |
| B symptoms, yes (vs no) | 1.69 | 0.80-3.57 | .17 | 2.00 | 0.78-5.20 | .16 |
| Stage, III-IV (vs I-II) | 1.89 | 0.95-3.73 | .07 | 1.37 | 0.59-3.16 | .46 |
| Lines before leukapheresis, ≥4 (vs <4) | 1.63 | 0.90-2.98 | .11 | 1.95 | 0.94-4.03 | .07 |
| LDH, U/L, >ULN (vs ≤) ULN | 1.75 | 0.95-3.24 | .07 | 3.39 | 1.19-9.67 | .02 |
| CRP, mg/mL, >30 (vs ≤ 30) | 1.58 | 0.91-2.76 | .11 | 2.20 | 1.09-4.42 | .02 |
| Ferritin, μg/L, >1 000 (vs <1 000) | 1.27 | 0.72-2.23 | .41 | 2.36 | 1.15-4.84 | .02 |
| MTV D−7, >80 (vs < 80) | 1.58 | 0.85-2.95 | .15 | 1.93 | 0.89-4.18 | .10 |
| mHLA-DR D−7, Ab/c <13 500 | 3.17 | 1.51-6.67 | .002 | 3.15 | 1.25-7.93 | .01 |
| Lymphoma subtype | ||||||
| DLBCL (vs tNHL) | 1.65 | 0.91-2.97 | .10 | 1.24 | 0.59-2.62 | .57 |
| PMBCL (vs tNHL) | 0.55 | 0.13-2.42 | .43 | 0.00 | 0.00-0.00 | .99 |
| Cell of origin, non-GC (vs GC) | 1.38 | 0.81-2.36 | .23 | 1.15 | 0.57-2.31 | .70 |
| Prior autologous transplant, Yes (vs no) | 1.19 | 0.67-2.10 | .56 | 1.39 | 0.66-2.93 | .38 |
| CAR T-cell type, Tisa-cel (vs axi-cel) | 2.04 | 1.21-3.45 | .008 | 1.59 | 0.79-3.20 | .19 |
F, female; GC, germinal center; M, male; PMBCL, primary mediastinal large B-cell lymphoma; tNHL, transformed non-Hodgkin lymphoma; ULN, upper limit of normal.
Bold indicates statistical significance.